Detalles de la búsqueda
1.
Osteogenic effects of a potent Src-over-Abl-selective kinase inhibitor in the mouse.
J Pharmacol Exp Ther
; 340(3): 676-87, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22171089
2.
Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors.
J Med Chem
; 64(15): 10772-10805, 2021 08 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34255512
3.
A cell-based Dkk1 binding assay reveals roles for extracellular domains of LRP5 in Dkk1 interaction and highlights differences between wild-type and the high bone mass mutant LRP5(G171V).
J Cell Biochem
; 108(5): 1066-75, 2009 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19746449
4.
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.
Oncogenesis
; 7(4): 35, 2018 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29674704
5.
Isogenic human cell lines for drug discovery: regulation of target gene expression by engineered zinc-finger protein transcription factors.
J Biomol Screen
; 10(4): 304-13, 2005 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15964931
6.
In vitro and in vivo activities of C-terminally truncated PTH peptides reveal a disconnect between cAMP signaling and functional activity.
Bone
; 35(6): 1263-72, 2004 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-15589208
7.
(1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: a wingless beta-catenin agonist that increases bone formation rate.
J Med Chem
; 52(22): 6962-5, 2009 Nov 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-19856966
Resultados
1 -
7
de 7
1
Próxima >
>>